Q32 Bio Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
QTTB Nasdaq 2834 www.q32bio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Q32 Bio Inc.

This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Dec 2nd, 2025 9:28 am
Top Midday Gainers - Dec 1st, 2025 11:32 am
BC-Most Active Stocks - Dec 1st, 2025 8:30 am
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - Dec 1st, 2025 6:40 am
Q32 Bio Sells Complement Inhibitor ADX-097 - Dec 1st, 2025 5:00 am
Akebia Announces Establishment of Rare Kidney Disease Pipeline - Dec 1st, 2025 5:00 am
Q32 Bio: Q3 Earnings Snapshot - Nov 13th, 2025 5:04 am
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 4:59 am
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata - Oct 21st, 2025 4:59 am
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference - Aug 28th, 2025 4:59 am
Q32 Bio: Q2 Earnings Snapshot - Aug 6th, 2025 5:04 am
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 6th, 2025 4:59 am
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer - Jun 25th, 2025 4:59 am
Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary - Jun 24th, 2025 11:06 am
OXB completes acquisition of remaining stake in US subsidiary - Jun 23rd, 2025 5:00 am
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 8th, 2025 4:59 am
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - Apr 30th, 2025 4:59 am
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - Apr 16th, 2025 4:59 am
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - Mar 11th, 2025 4:59 am
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting - Mar 8th, 2025 9:00 am